{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:45Z","timestamp":1759536045473,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151352","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T18:34:48Z","timestamp":1685385288000},"page":"151352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease"],"prefix":"10.1016","volume":"42","author":[{"given":"Shonali","family":"Midha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umut","family":"Selamet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2023.151352_bib0001","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0002","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0003","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0004","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9983","key":"10.1016\/j.semnephrol.2023.151352_bib0005","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0006","first-page":"665","article-title":"myloidosis (AL). Clinical and laboratory features in 229 cases","volume":"58","author":"Kyle","year":"1983","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0007","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2002-06-1698","article-title":"Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0008","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0009","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia."},{"key":"10.1016\/j.semnephrol.2023.151352_bib0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"van de Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151352_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151352_bib0012","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151352_bib0013","first-page":"243","article-title":"Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151352_bib0014","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1681\/ASN.2017121319","article-title":"The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases","volume":"29","author":"Sethi","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151352_bib0015","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4065\/81.12.1575","article-title":"Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays","volume":"81","author":"Katzmann","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0016","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151352_bib0017","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"S1","key":"10.1016\/j.semnephrol.2023.151352_bib0018","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.5045\/br.2020.S009","article-title":"AL amyloidosis: advances in diagnosis and management","volume":"55","author":"Koh","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0019","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151352_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0022","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0023","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2023.151352_bib0024","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2022-165371","article-title":"Evolving pattern improves the IMWG 2\/20\/20 classification for patients with smoldering multiple myeloma","volume":"140","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0025","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0026","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0027","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0028","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.semnephrol.2023.151352_bib0029","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0031","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.18632\/oncotarget.23412","article-title":"Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients","volume":"9","author":"Steiner","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151352_bib0032","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151352_bib0033","doi-asserted-by":"crossref","first-page":"E310","DOI":"10.1016\/j.clml.2019.09.509","article-title":"The PROMISE study: a nationwide project for predicting the progression of developing myeloma in a high-risk screened population","volume":"19","author":"Cowan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151352_bib0034","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40620-018-0492-4","article-title":"Myeloma light chain cast nephropathy, a review","volume":"32","author":"Sathick","year":"2019","journal-title":"J Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.5858\/2004-128-875-RPSIAA","article-title":"Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia","volume":"128","author":"Herrera","year":"2004","journal-title":"Arch Pathol Lab Med."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151352_bib0036","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.semnephrol.2023.151352_bib0037","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.2019003807","article-title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","volume":"135","author":"Royal","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151352_bib0038","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151352_bib0039","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151352_bib0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.kint.2016.10.022","article-title":"New insights into the pathogenesis and treatment of heavy chain deposition disease","volume":"91","author":"Hogan","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151352_bib0041","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151352_bib0042","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151352_bib0043","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151352_bib0044","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1681\/ASN.2015050581","article-title":"Impaired lysosomal function underlies monoclonal light chain-associated renal Fanconi syndrome","volume":"27","author":"Luciani","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151352_bib0045","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151352_bib0046","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1046\/j.1523-1755.2002.00628.x","article-title":"Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features","volume":"62","author":"Bridoux","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151352_bib0047","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151352_bib0048","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2015.195","article-title":"Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits","volume":"88","author":"Larsen","year":"2015","journal-title":"Kidney Int"},{"issue":"10068","key":"10.1016\/j.semnephrol.2023.151352_bib0049","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151352_bib0050","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151352_bib0051","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151352_bib0052","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10192","key":"10.1016\/j.semnephrol.2023.151352_bib0053","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151352_bib0054","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151352_bib0055","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151352_bib0056","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10301","key":"10.1016\/j.semnephrol.2023.151352_bib0057","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151352_bib0058","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151352_bib0059","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151352_bib0060","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2019031914","article-title":"Pathophysiology and management of monoclonal gammopathy of renal significance","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151352_bib0061","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151352_bib0062","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:42:54Z","timestamp":1759448574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000621"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151352","relation":{},"ISSN":["0270-9295"],"issn-type":[{"type":"print","value":"0270-9295"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151352"}}